Recent biotech winnersRight then, the juicy bits you’ve probably been waiting for in this piece – biotech stock success stories to date for the fund, and its top picks looking ahead. Some, have already actually been mentioned.Starting with recent excellent performers, Chapman said the ones driving the fund’s success over the past few months include: Arovella Therapeutics (ASX:ALA), PharmAust (ASXAA), Neurotech (ASX:NTI), and Neuren Pharmaceuticals (ASX:NEU).“These ones are have all been long-term holds, so they aren’t new additions, but they’ve all been winners of late,” he said, noting that the firm did sell out of NEU recently.As for stocks that Chapman believes are primed for a rally in favourable conditions this year, he has four…
NEU Price at posting:
$20.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
AA), Neurotech (ASX:NTI), and Neuren Pharmaceuticals (ASX:NEU).“These ones are have all been long-term holds, so they aren’t new additions, but they’ve all been winners of late,” he said, noting that the firm did sell out of NEU recently.As for stocks that Chapman believes are primed for a rally in favourable conditions this year, he has four…
(20min delay)